tetano
Editor, Senior Moderator
Nat Commun
. 2025 Oct 6;16(1):8876.
doi: 10.1038/s41467-025-63948-4. Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Nonhlanhla N Mkhize[SUP] #[/SUP][SUP] 1 2 [/SUP], Bo Zhang[SUP] #[/SUP][SUP] 3 [/SUP], Caroline Brackett[SUP] #[/SUP][SUP] 4 [/SUP], Peter James Elyanu[SUP] 5 [/SUP], Asa Tapley[SUP] 3 6 7 [/SUP], Sufia Dadabhai[SUP] 8 [/SUP], Jiani Hu[SUP] 3 [/SUP], Bich T N Do[SUP] 4 [/SUP], Daniel J Schuster[SUP] 4 [/SUP], Jack Heptinstall[SUP] 4 [/SUP], Sheetal Sawant[SUP] 4 [/SUP], Kelly Seaton[SUP] 4 [/SUP], Marcella Sarzotti-Kelsoe[SUP] 4 [/SUP], Aaron Hudson[SUP] 3 9 10 [/SUP], Yutong Jin[SUP] 3 [/SUP], Sinethemba Bhebhe[SUP] 1 2 [/SUP], Haajira Kaldine[SUP] 1 2 [/SUP], Prudence Kgagudi[SUP] 1 2 [/SUP], Tandile Modise[SUP] 1 2 [/SUP], Nyaradzo M Mgodi[SUP] 11 [/SUP], Jessica Andriesen[SUP] 3 [/SUP], April K Randhawa[SUP] 3 [/SUP], Leigh H Fisher[SUP] 3 [/SUP], Jia Jin Kee[SUP] 3 [/SUP], Craig A Magaret[SUP] 3 [/SUP], James Peng[SUP] 9 [/SUP], Avi Kenny[SUP] 12 13 [/SUP], Lindsay N Carpp[SUP] 3 [/SUP], Zhe Chen[SUP] 14 [/SUP], Siyu Heng[SUP] 15 [/SUP], Manuel Villaran[SUP] 3 [/SUP], Azwidihwi Takalani[SUP] 16 [/SUP], Bert Le Roux[SUP] 16 [/SUP], Eduan Wilkinson[SUP] 17 18 [/SUP], Jackline Odhiambo[SUP] 3 16 [/SUP], Parth Shah[SUP] 10 [/SUP], Laura Polakowski[SUP] 19 [/SUP], Margaret Yacovone[SUP] 19 [/SUP], Taraz Samandari[SUP] 20 [/SUP], Zvavahera Chirenje[SUP] 11 [/SUP], Joseph Makhema[SUP] 21 [/SUP], Ethel Kamuti[SUP] 22 [/SUP], Katanekwa Njekwa[SUP] 22 [/SUP], Harriet Nuwagaba-Biribonwoha[SUP] 23 24 [/SUP], Allan Baguma[SUP] 5 [/SUP], Sharlaa Badal-Faesen[SUP] 25 [/SUP], William Brumskine[SUP] 26 [/SUP], Soritha Coetzer[SUP] 27 [/SUP], Rodney Dawson[SUP] 28 [/SUP], Sinead Delany-Moretlwe[SUP] 29 [/SUP], Andreas Henri Diacon[SUP] 30 [/SUP], Samantha Fry[SUP] 31 [/SUP], Katherine Gill[SUP] 32 [/SUP], Anda Madikida[SUP] 32 [/SUP], Zaheer Ahmed Ebrahim Hoosain[SUP] 33 [/SUP], Mina C Hosseinipour[SUP] 34 35 [/SUP], Mubiana Inambao[SUP] 36 [/SUP], Craig Innes[SUP] 37 [/SUP], Steve Innes[SUP] 32 [/SUP], Dishiki Kalonji[SUP] 38 [/SUP], Humphrey Mwape[SUP] 39 [/SUP], Priya Kassim[SUP] 40 [/SUP], Melvin C Kamanga[SUP] 41 [/SUP], William Kilembe[SUP] 42 [/SUP], Fatima Laher[SUP] 43 [/SUP], Mookho Malahleha[SUP] 44 [/SUP], Vongane Louisa Maluleke[SUP] 45 [/SUP], Grace Mboya[SUP] 46 [/SUP], Philister Adhiambo Madiega[SUP] 47 [/SUP], Kirsten McHarry[SUP] 48 [/SUP], Essack Mitha[SUP] 49 [/SUP], Yajna Duki[SUP] 50 [/SUP], Pamela Mda[SUP] 51 [/SUP], Moroesi Moerane[SUP] 51 [/SUP], Tumelo Moloantoa[SUP] 52 [/SUP], Simpson Nuwamanya[SUP] 53 [/SUP], Sharana Mahomed[SUP] 54 [/SUP], Vimla Naicker[SUP] 55 [/SUP], Anusha Nana[SUP] 40 [/SUP], Annet Nanvubya[SUP] 56 [/SUP], Barbarah Kawoozo[SUP] 56 [/SUP], Maphoshane Nchabeleng[SUP] 57 [/SUP], Walter Otieno[SUP] 58 59 [/SUP], Elsje Louise Potgieter[SUP] 60 [/SUP], Disebo Potloane[SUP] 54 [/SUP], Zelda Punt[SUP] 61 [/SUP], Jamil Said[SUP] 62 [/SUP], Yashna Singh[SUP] 32 [/SUP], Sheetal Kassim[SUP] 32 [/SUP], Dorothie van der Vendt[SUP] 32 [/SUP], Mohammed Siddique Tayob[SUP] 63 [/SUP], Yacoob Vahed[SUP] 64 [/SUP], Deo Ogema Wabwire[SUP] 65 [/SUP], James G Kublin[SUP] 3 [/SUP], Linda-Gail Bekker[SUP] 32 [/SUP], Lawrence Corey[SUP] 3 [/SUP], Glenda E Gray[SUP] 66 [/SUP], Yunda Huang[SUP] 3 67 [/SUP], Philip Kotze[SUP] 68 [/SUP], Nigel Garrett[SUP] 32 54 69 [/SUP], John Hural[SUP] 3 [/SUP], Guido Ferrari[SUP] 4 [/SUP], Erica Andersen-Nissen[SUP] 3 70 [/SUP], David Montefiori[SUP] 4 [/SUP], Penny L Moore[SUP] 1 2 54 [/SUP], M Juliana McElrath[SUP] 3 [/SUP], Georgia D Tomaras[SUP] 71 [/SUP], Peter B Gilbert[SUP] 72 73 74 [/SUP]; CoVPN 3008 Study Team
Affiliations
People with HIV (PWH) are understudied in COVID-19 vaccine trials, leaving knowledge gaps on whether the identified immune correlates of protection also hold in PWH. CoVPN 3008 (NCT05168813) enrolled predominantly PWH and reported lower COVID-19 incidence for a Hybrid vs. Vaccine Group (baseline SARS-CoV-2-positive and one mRNA-1273 dose vs. negative and two doses). Using case-cohort sampling, antibody markers at enrolment (M0) and four weeks post-final vaccination (Peak) are assessed as immune correlates of COVID-19. For the Hybrid Group [n = 287 (195 PWH)], all M0 markers inversely correlate with COVID-19 through 230 days post-Peak, with 50% inhibitory dilution BA.4/5 neutralizing antibody titer (nAb-ID50 BA.4/5) the strongest and only independent correlate (HR per 10-fold increase=0.46, 95% CI 0.28, 0.75; P = 0.002). For the Vaccine Group [n = 115 (86 PWH)], Peak nAb-ID50 BA.4/5 correlates with reduced COVID-19 risk (1.9%, 1.1%, and 0.3% at titers 10, 100, and 1000 AU/ml) through 92, but not 165, days post-Peak. Using multivariable Cox analysis of binding and nAb, nAb titers predict COVID-19 in PWH. Two doses of a 100-µg Ancestral strain mRNA vaccine in baseline-SARS-CoV-2-negative individuals elicit sufficient cross-reacting Omicron antibodies to reduce COVID-19 incidence for 90 days post-Peak, but viral evolution and waning antibodies abrogate this protection thereafter.
. 2025 Oct 6;16(1):8876.
doi: 10.1038/s41467-025-63948-4. Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Nonhlanhla N Mkhize[SUP] #[/SUP][SUP] 1 2 [/SUP], Bo Zhang[SUP] #[/SUP][SUP] 3 [/SUP], Caroline Brackett[SUP] #[/SUP][SUP] 4 [/SUP], Peter James Elyanu[SUP] 5 [/SUP], Asa Tapley[SUP] 3 6 7 [/SUP], Sufia Dadabhai[SUP] 8 [/SUP], Jiani Hu[SUP] 3 [/SUP], Bich T N Do[SUP] 4 [/SUP], Daniel J Schuster[SUP] 4 [/SUP], Jack Heptinstall[SUP] 4 [/SUP], Sheetal Sawant[SUP] 4 [/SUP], Kelly Seaton[SUP] 4 [/SUP], Marcella Sarzotti-Kelsoe[SUP] 4 [/SUP], Aaron Hudson[SUP] 3 9 10 [/SUP], Yutong Jin[SUP] 3 [/SUP], Sinethemba Bhebhe[SUP] 1 2 [/SUP], Haajira Kaldine[SUP] 1 2 [/SUP], Prudence Kgagudi[SUP] 1 2 [/SUP], Tandile Modise[SUP] 1 2 [/SUP], Nyaradzo M Mgodi[SUP] 11 [/SUP], Jessica Andriesen[SUP] 3 [/SUP], April K Randhawa[SUP] 3 [/SUP], Leigh H Fisher[SUP] 3 [/SUP], Jia Jin Kee[SUP] 3 [/SUP], Craig A Magaret[SUP] 3 [/SUP], James Peng[SUP] 9 [/SUP], Avi Kenny[SUP] 12 13 [/SUP], Lindsay N Carpp[SUP] 3 [/SUP], Zhe Chen[SUP] 14 [/SUP], Siyu Heng[SUP] 15 [/SUP], Manuel Villaran[SUP] 3 [/SUP], Azwidihwi Takalani[SUP] 16 [/SUP], Bert Le Roux[SUP] 16 [/SUP], Eduan Wilkinson[SUP] 17 18 [/SUP], Jackline Odhiambo[SUP] 3 16 [/SUP], Parth Shah[SUP] 10 [/SUP], Laura Polakowski[SUP] 19 [/SUP], Margaret Yacovone[SUP] 19 [/SUP], Taraz Samandari[SUP] 20 [/SUP], Zvavahera Chirenje[SUP] 11 [/SUP], Joseph Makhema[SUP] 21 [/SUP], Ethel Kamuti[SUP] 22 [/SUP], Katanekwa Njekwa[SUP] 22 [/SUP], Harriet Nuwagaba-Biribonwoha[SUP] 23 24 [/SUP], Allan Baguma[SUP] 5 [/SUP], Sharlaa Badal-Faesen[SUP] 25 [/SUP], William Brumskine[SUP] 26 [/SUP], Soritha Coetzer[SUP] 27 [/SUP], Rodney Dawson[SUP] 28 [/SUP], Sinead Delany-Moretlwe[SUP] 29 [/SUP], Andreas Henri Diacon[SUP] 30 [/SUP], Samantha Fry[SUP] 31 [/SUP], Katherine Gill[SUP] 32 [/SUP], Anda Madikida[SUP] 32 [/SUP], Zaheer Ahmed Ebrahim Hoosain[SUP] 33 [/SUP], Mina C Hosseinipour[SUP] 34 35 [/SUP], Mubiana Inambao[SUP] 36 [/SUP], Craig Innes[SUP] 37 [/SUP], Steve Innes[SUP] 32 [/SUP], Dishiki Kalonji[SUP] 38 [/SUP], Humphrey Mwape[SUP] 39 [/SUP], Priya Kassim[SUP] 40 [/SUP], Melvin C Kamanga[SUP] 41 [/SUP], William Kilembe[SUP] 42 [/SUP], Fatima Laher[SUP] 43 [/SUP], Mookho Malahleha[SUP] 44 [/SUP], Vongane Louisa Maluleke[SUP] 45 [/SUP], Grace Mboya[SUP] 46 [/SUP], Philister Adhiambo Madiega[SUP] 47 [/SUP], Kirsten McHarry[SUP] 48 [/SUP], Essack Mitha[SUP] 49 [/SUP], Yajna Duki[SUP] 50 [/SUP], Pamela Mda[SUP] 51 [/SUP], Moroesi Moerane[SUP] 51 [/SUP], Tumelo Moloantoa[SUP] 52 [/SUP], Simpson Nuwamanya[SUP] 53 [/SUP], Sharana Mahomed[SUP] 54 [/SUP], Vimla Naicker[SUP] 55 [/SUP], Anusha Nana[SUP] 40 [/SUP], Annet Nanvubya[SUP] 56 [/SUP], Barbarah Kawoozo[SUP] 56 [/SUP], Maphoshane Nchabeleng[SUP] 57 [/SUP], Walter Otieno[SUP] 58 59 [/SUP], Elsje Louise Potgieter[SUP] 60 [/SUP], Disebo Potloane[SUP] 54 [/SUP], Zelda Punt[SUP] 61 [/SUP], Jamil Said[SUP] 62 [/SUP], Yashna Singh[SUP] 32 [/SUP], Sheetal Kassim[SUP] 32 [/SUP], Dorothie van der Vendt[SUP] 32 [/SUP], Mohammed Siddique Tayob[SUP] 63 [/SUP], Yacoob Vahed[SUP] 64 [/SUP], Deo Ogema Wabwire[SUP] 65 [/SUP], James G Kublin[SUP] 3 [/SUP], Linda-Gail Bekker[SUP] 32 [/SUP], Lawrence Corey[SUP] 3 [/SUP], Glenda E Gray[SUP] 66 [/SUP], Yunda Huang[SUP] 3 67 [/SUP], Philip Kotze[SUP] 68 [/SUP], Nigel Garrett[SUP] 32 54 69 [/SUP], John Hural[SUP] 3 [/SUP], Guido Ferrari[SUP] 4 [/SUP], Erica Andersen-Nissen[SUP] 3 70 [/SUP], David Montefiori[SUP] 4 [/SUP], Penny L Moore[SUP] 1 2 54 [/SUP], M Juliana McElrath[SUP] 3 [/SUP], Georgia D Tomaras[SUP] 71 [/SUP], Peter B Gilbert[SUP] 72 73 74 [/SUP]; CoVPN 3008 Study Team
Affiliations
- PMID: 41053137
- DOI: 10.1038/s41467-025-63948-4
People with HIV (PWH) are understudied in COVID-19 vaccine trials, leaving knowledge gaps on whether the identified immune correlates of protection also hold in PWH. CoVPN 3008 (NCT05168813) enrolled predominantly PWH and reported lower COVID-19 incidence for a Hybrid vs. Vaccine Group (baseline SARS-CoV-2-positive and one mRNA-1273 dose vs. negative and two doses). Using case-cohort sampling, antibody markers at enrolment (M0) and four weeks post-final vaccination (Peak) are assessed as immune correlates of COVID-19. For the Hybrid Group [n = 287 (195 PWH)], all M0 markers inversely correlate with COVID-19 through 230 days post-Peak, with 50% inhibitory dilution BA.4/5 neutralizing antibody titer (nAb-ID50 BA.4/5) the strongest and only independent correlate (HR per 10-fold increase=0.46, 95% CI 0.28, 0.75; P = 0.002). For the Vaccine Group [n = 115 (86 PWH)], Peak nAb-ID50 BA.4/5 correlates with reduced COVID-19 risk (1.9%, 1.1%, and 0.3% at titers 10, 100, and 1000 AU/ml) through 92, but not 165, days post-Peak. Using multivariable Cox analysis of binding and nAb, nAb titers predict COVID-19 in PWH. Two doses of a 100-µg Ancestral strain mRNA vaccine in baseline-SARS-CoV-2-negative individuals elicit sufficient cross-reacting Omicron antibodies to reduce COVID-19 incidence for 90 days post-Peak, but viral evolution and waning antibodies abrogate this protection thereafter.